A Multicenter, Randomized, Double-blind Phase III Study SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage Female Breast Cancer
Latest Information Update: 06 Aug 2024
At a glance
- Drugs Dalpiciclib (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 01 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 20 May 2021 Status changed from not yet recruiting to recruiting.
- 16 Apr 2021 New trial record